Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Herpes simplex virus type 2 (HSV-2), a globally sexually transmitted virus, and also one of the main causes of genital ulcer diseases, increases susceptibility to HIV-1. Effective vaccines to prevent HSV-2 infection are not yet available, but are currently being developed. To facilitate this process, the latest progress in development of these vaccines is reviewed in this paper. A summary of the most promising HSV-2 vaccines tested in animals in the last five years is presented, including the main factors, and new ideas for developing an effective vaccine from animal experiments and human clinical trials. Experimental results indicate that future HSV-2 vaccines may depend on a strategy that targets mucosal immunity. Furthermore, estradiol, which increases the effectiveness of vaccines, may be considered as an adjuvant. Therefore, this review is expected to provide possible strategies for development of future HSV-2 vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939461 | PMC |
| http://dx.doi.org/10.3390/v6020371 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Development and immunogenicity evaluation in mice of a novel mRNA vaccine expressing herpes simplex virus type 2 envelope glycoprotein gD].
Sheng Wu Gong Cheng Xue Bao
August 2025
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Human alphaherpesvirus 2 (HSV-2) is the main pathogen resulting human genital herpes, which poses a major threat to the socio-economic development, while there is no effective vaccine. In this study, we developed a novel lipopolyplex (LPP)-delivered mRNA vaccine expressing the HSV-2 envelope glycoprotein gD and evaluated its immunogenicity in mice. The mRNA vaccine was prepared from the genetically modified gD mRNA synthesized combined with the LPP delivery platform and it was named gD-ORI mRNA.
View Article and Find Full Text PDFThe prevalence of nine human herpesviruses in urogenital samples from young women in Finland.
BMC Infect Dis
August 2025
Department of Virology, University of Helsinki, PO Box 21, 00014, Helsinki, Finland.
Background: Beyond herpes simplex virus (HSV), the pathogenic role and occurrence of other human herpesviruses (HHVs) in the genitourinary tract remain largely unclear. This study aimed to determine the prevalence and level of shedding of nine typical human-infecting herpesviruses in genitourinary specimens of young women.
Methods: We investigated the prevalence and quantity of HHVs using qPCR in urogenital samples from 380 women participating in a community-randomized human papillomavirus (HPV) vaccination trial and in a randomized trial on the effectiveness of Chlamydia trachomatis screening.
Antibodies targeting HSV glycoprotein B require effector functions to protect neonatal mice.
bioRxiv
July 2025
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
Glycoprotein B (gB) serves as the viral fusion protein for herpes simplex virus (HSV), mediating fusion between viral and host membranes resulting in infection. As such, gB represents a potentially critical target for the host immune system with high potential relevance for vaccine design. Here we investigated the mechanisms of protection for a panel of gB-specific monoclonal antibodies (mAb) in a mouse model of neonatal HSV (nHSV) infection.
View Article and Find Full Text PDFSmall molecule UCM05 inhibits HSV-2 infection via targeting viral glycoproteins and fatty acid synthase with potentiating antiviral immunity.
Virol J
July 2025
Dermatology Hospital, Southern Medical University, Guangzhou, 510091, China.
Herpes simplex virus type 2 (HSV-2) is a highly prevalent human pathogen worldwide that not only causes genital herpes but is also associated with severe health complications, such as neonatal infections and increased susceptibility to HIV. Currently, due to the lack of an effective HSV-2 vaccine and the emergence of more drug-resistant strains, there is an urgent need to develop effective, safe, and affordable anti-HSV-2 medications. The small molecule UCM05 is a novel inhibitor of fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz), with antitumor and antibacterial effects.
View Article and Find Full Text PDFGenital herpes shedding episodes associate with alterations in the spatial organization and activation of mucosal immune cells.
bioRxiv
June 2025
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Herpes Simplex Virus 2 (HSV-2) infection results in variable rates of local viral shedding in anogenital skin. The impact of episodic viral exposures on immune cells in adjacent mucosal tissues, including the genital tract, is unknown. However, any immune responses at this site could impact protective mucosal immunity, tissue homeostasis, and adverse health outcomes.
View Article and Find Full Text PDF